Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR5 | Q9H228 | 5/20 | 0.57 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.57 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | BCHE | P06276 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.49 |
| ▸ | SCN4A | P35499 | 2/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL51880 | 1.00 | S1PR5 (0.57) | S1PR5S1PR1LTA4HBCHEALDH1A1 | |
| SCHEMBL4023553 | 0.94 | S1PR5 (0.52) | S1PR5S1PR1LTA4HBCHEALDH1A1 | |
| SCHEMBL6616917 | 0.94 | S1PR5 (0.60) | S1PR5S1PR1LTA4HALDH1A1MAPT | |
| SCHEMBL1439237 | 0.92 | S1PR5 (0.52) | S1PR5S1PR1LTA4HBCHEALDH1A1 | |
| SCHEMBL29067901 | 0.92 | S1PR5 (0.52) | S1PR5S1PR1LTA4HBCHEALDH1A1 | |
| SCHEMBL1439927 | 0.90 | S1PR5 (0.51) | S1PR5S1PR1LTA4HBCHEALDH1A1 | |
| SCHEMBL29067832 | 0.90 | S1PR5 (0.51) | S1PR5S1PR1LTA4HBCHEALDH1A1 | |
| SCHEMBL8321624 | 0.88 | KDM4E (0.54) | S1PR5S1PR1LTA4HALDH1A1MAPT | |
| SCHEMBL6749184 | 0.87 | S1PR5 (0.50) | S1PR5S1PR1LTA4HALDH1A1MAPT | |
| SCHEMBL29080062 | 0.87 | NR1H2 (0.49) | S1PR5S1PR1LTA4HBCHEMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129398-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-06 | — | — | US | disclosed |
| US-20090253677-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253677-A1 | HIV Integrase Inhibitors | DNTT, POLB, UNG | S1PR5 4454/4885S1PR1 4182/4885LTA4H 2613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.